GlassScriptPhysician profile
Eric P Fontenot
NPI 1437228657
$1,014.62
in general payments reported to CMS, 2019-2025
21 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $144 · 2021: $80.58 · 2022: $84.20 · 2023: $31.04 · 2024: $127 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $304.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $196.42 | 2019-2025 | Jardiance, Mounjaro |
| Amgen INC. | $106.17 | 2019-2024 | Enbrel |
| Astrazeneca Pharmaceuticals LP | $104.23 | 2019-2024 | Airsupra |
| Abbvie INC. | $102.62 | 2019-2025 | |
| Amarin Pharma, INC. | $97.53 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.86 | 2020-2022 | |
| Pfizer INC. | $41.28 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.78 | 2020-2022 | |
| Shire North American Group INC | $36.28 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.77 | 2019-2020 | |
| Apollo Endosurgery US INC | $27.48 | 2021 | |
| Almirall LLC | $21.67 | 2019 | |
| Janssen Biotech, INC. | $18.80 | 2025 | Tremfya |
| Currax Pharmaceuticals LLC | $17.42 | 2023 | Contrave |
| Genentech USA, INC. | $17.02 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $16.61 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.89 | 2024 | Quviviq |
| Phadia US INC. | $14.85 | 2024 | Immunocap |
| Kowa Pharmaceuticals America, INC. | $13.81 | 2022 | |
| Allergan, INC. | $11.69 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Fontenot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.